Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors

References

• Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 343–349.
   Google Scholar
• Tsao L, His ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209–1218.
   PubMed Web of Science ®Google Scholar
• DiNardo CE, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 2010;17:368–374.
   PubMed Web of Science ®Google Scholar
• Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429–436.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Schumacher M. Bootstrap and cross validation to access complexity of data-driven regression models. In: Brause RW, Hanisch, E, editors. ISMDA ‘00 Proceedings of the First International Symposium on Medical Data Analysis. London: Springer-Verlag; 2000. pp. 234–241.
   Google Scholar
• Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease:outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038–1046.
   PubMed Web of Science ®Google Scholar
• Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica 2011;96:1067–1071.
   PubMed Web of Science ®Google Scholar
• Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression:issues in prespective. Transplantation 2011;91:1057–1064.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gilbert ES, Rizzo DJ, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992–5001.
   PubMed Web of Science ®Google Scholar
• Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011;86:206–209.
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328–1337.
   PubMed Web of Science ®Google Scholar
• Küppers R. B cells under influence:transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801–812.
   PubMed Web of Science ®Google Scholar
• Mortin LM, Landgren O, Chatterjee N, et al. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood 2007;110:4599–4605.
   PubMed Web of Science ®Google Scholar
• Mattila PS, Aalto SM, Heikkilä L, et al. Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001;15:337–342.
   PubMed Web of Science ®Google Scholar
• Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901–2906.
   PubMed Web of Science ®Google Scholar
• Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005;104:1661–1667.
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantion lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053–3057.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007;92:1489–1494.
   PubMed Web of Science ®Google Scholar
• Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007;86:599–607.
   PubMed Web of Science ®Google Scholar
• Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196–206.
   PubMed Web of Science ®Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2001;11:336–347.
   Web of Science ®Google Scholar
• Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008;86:215–222.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007;41:1648–1659.
   PubMed Web of Science ®Google Scholar
• Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772–778.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Habermann TH, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574–7582.
   PubMed Web of Science ®Google Scholar
• Hourigan MJ, Doecke J, Mollee PN, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol 2008;141:904–907.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Tejanj AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002;2:993–998.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2001;86:124–128.
   Web of Science ®Google Scholar
• Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma:a randomized phase 3 trial. Lancet Oncol 2011;12:773–784.
   PubMed Web of Science ®Google Scholar
• Gärtner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol 2010;48:82–90.
   PubMed Web of Science ®Google Scholar
• Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010;23:350–366.
   PubMed Web of Science ®Google Scholar